Compare AGM & MIRM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | AGM | MIRM |
|---|---|---|
| Founded | 1987 | 2018 |
| Country | United States | United States |
| Employees | 212 | N/A |
| Industry | Finance Companies | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.9B | 5.7B |
| IPO Year | N/A | 2019 |
| Metric | AGM | MIRM |
|---|---|---|
| Price | $177.08 | $97.27 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 1 | 13 |
| Target Price | ★ $215.00 | $119.85 |
| AVG Volume (30 Days) | 88.2K | ★ 1.0M |
| Earning Date | 05-05-2026 | 05-06-2026 |
| Dividend Yield | ★ 3.71% | N/A |
| EPS Growth | N/A | ★ 74.59 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $19,138,000.00 |
| Revenue This Year | $25.97 | $26.22 |
| Revenue Next Year | $12.21 | $22.04 |
| P/E Ratio | $9.95 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $136.57 | $43.40 |
| 52 Week High | $210.64 | $114.99 |
| Indicator | AGM | MIRM |
|---|---|---|
| Relative Strength Index (RSI) | 55.95 | 45.97 |
| Support Level | $172.10 | $95.68 |
| Resistance Level | $178.73 | $98.03 |
| Average True Range (ATR) | 4.67 | 5.94 |
| MACD | -0.44 | -1.05 |
| Stochastic Oscillator | 44.30 | 15.08 |
Federal Agricultural Mortgage Corp provides agricultural real estate and rural housing mortgage loans in the secondary market in the U.S. Its operations consist of seven reportable segments: Farm & Ranch, which generates maximum revenue, Corporate AgFinance, Power & Utilities, Broadband Infrastructure, Renewable Energy, Funding, and Investments. The company purchases eligible mortgage loans secured by first liens on agricultural real estate and rural housing under the Farm & Ranch line of business. Its subsidiary purchases portions of certain agricultural, rural development, business and industry, and community facilities loans guaranteed by the USDA. Geographically, the company's operations are spread across different regions in the United States.
Mirum Pharmaceuticals Inc. is a biopharmaceutical company focused on developing and commercializing therapies for rare and orphan diseases. Its main product, Livmarli (maralixibat), is an orally administered IBAT inhibitor approved to treat cholestatic pruritus in patients with Alagille syndrome. The company is also developing treatments such as maralixibat for PFIC and ALGS, and volixibat for adult cholestatic liver diseases. Mirum currently has three approved medicines: Livmarli, Cholbam, and Ctexli.